Researchers investigated the risk of cardiovascular events in patients with MPN and atrial fibrillation, and evaluated the predictive value of traditional risk scores.
Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera.
The careful consideration of cancer risk is especially important during the first year after the presentation of pruritus.
Rusfertide demonstrated activity in reducing hematocrit levels in patients with polycythemia vera in two phase 2 clinical trials.
Gender balance in cancer surveys was found to have relatively little effect on survey outcomes, according to results of a study presented at the 2022 ASCO Annual Meeting. Surveying patients with myeloproliferative neoplasms (MPN) has given valuable insight into polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) subtypes. However, independent surveys have included a…
Findings from a retrospective study identified risk factors for thrombosis in patients with post-polycythemia vera myelofibrosis, compared with patients with polycythemia vera.
A case study highlights a potential adverse effect of prolonged hydroxyurea therapy in a patient with polycythemia vera.
Researchers sought to determine the prevalence of frailty among patients with myeloproliferative neoplasms.
Analysis of data from 2 clinical trials sought to determine the effect on symptom burden of 2 common therapies for myeloproliferative neoplasms.
Researchers sought to determine the effect of diagnosis and treatment on response to COVID-19 vaccination among patients with myeloproliferative neoplasms.
